I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis.
I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God.
I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree.
Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons.
I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA.
While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon..
In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God.
We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987).
From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting.
Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982.
I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects.
In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston.
In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018.
Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia.
In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey.
As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova.
Love and God Bless,
Peter – aka RJ Hamster Jo hi
This is meant to be the bill that finally gives the US crypto industry the regulatory framework it’s been begging Washington for. Instead, it’s turned into Warren’s whipping mule…
The Senate Banking Committee is heading into Thursday’s CLARITY Act markup with over 100 amendments sitting in its inbox, including more than 40 from Elizabeth Warren on her own.
How much does she really hate crypto!
The bill itself is 309 pages, banking lobbyists have fired off something like 8,000 letters into Senate offices, Democrats are threatening to torpedo the whole thing over ethics, and Republicans are nervously[1] on the edges of their seats.
In short, one of the most significant pieces of legislation in crypto ever is getting well and truly politicked.
This is meant to be the bill that finally gives the US crypto industry the regulatory framework it’s been begging Washington for since the Obama years. Instead, it’s turned into Warren’s whipping mule and may end up about as useful as a flyscreen on a submarine.
So, the obvious question is, will we ever get clarity in crypto and then CLARITY? And if we do, will it end up causing more harm than good, effectively derailing the incoming bull run?
A bill in name only
Let’s look at what’s actually happening.
What happens with this sort of thing is wild when you really look at it. And is a reflection of how nonsensical politics and the legislative process really are.
The Senate Banking Committee dropped a 309-page draft on Monday night. Committee members got 48 hours to file amendments.
When was the last time you absorbed a 309 page document in 48 hours?
Years ago, I got into a Tesla-heavy fund before anyone believed in him. That single bet turned into nearly a seven-figure position in less than a decade.
Now I’m betting on Elon again – with SpaceX.
Bloomberg is calling it “the biggest listing of ALL TIME.” A $1.5 TRILLION valuation. A “millionaire-maker” event!
I believe Elon will announce the IPO any day now. And I have an “access code” that lets you get a stake in before it happens.*
Me thinks either junior staffers were busy (which is concerning in its own right), or AI was busy (which is maybe more concerning).[2]
Warren on her own filed 40-plus changes (must have a stacked team of staffers), including one that would block crypto firms from ever getting Federal Reserve master accounts.
Seems like she’s very much against the inevitability of the “stablefication of TradFi” I’ve been writing about to you for a while now.
According to reports, even if the committee advances the bill on Thursday, it still needs 60 votes on the Senate floor, then reconciliation with the House. The White House wanted it done by July 4th… yeah, that’s not happening.
Realistically if we get it this year, that’s probably a win for the industry.
Watered down anyway
Even in the best case, where this thing eventually gets signed into law, what comes out the other end is not going to be the clean framework the industry has been pushing for.
It’ll be a compromise of compromises.
Stablecoin yield restrictions the banks are happy with, but crypto firms work around. DeFi protections that look good on paper but fold in the real world. SEC and CFTC jurisdictions carved up so badly that lawyers spend the next decade arguing over who gets to preside over what.
So no, I don’t think we get CLARITY in any meaningful sense this year. And if it does come, I now don’t think it will actually provide any clarity.
I had hopes this would be a watershed moment for crypto.
Then the politicians stepped in and did their best politicking.
But for all the coverage of this (guilty!) there is something you should know.
While the Senate spends another summer arguing about whether software developers count as money transmitters, bitcoin will cross $100,000 again. Then $250,000. Then $500,000. Then a million.
How much clarity you want, comes down to how high the market rips in the coming bull market.
In essence, the industry needs this, but in reality, you don’t. You want a bull market, and my view is you’ll get one.
*This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201.
The Crypto Alarm is free today, owned and operated by Everest Media Brands LLC. But if you enjoyed this post, you can tell The Crypto Alarm that their writing is valuable by pledging a future subscription. You won’t be charged unless they enable payments.
I believe we’re in the final stretch before this story becomes impossible to ignore.
Once Wall Street fully mobilizes… once the media turns this into a daily countdown… once more investors start rushing for any way to get exposure…
The early positioning window disappears.
That’s why I’ve been pounding the table on this.
SpaceX could become the biggest IPO in Wall Street history.
And while most people assume they have to wait until after the public debut, I’ve already shown there’s a backdoor way to get positioned before that happens.
But this only matters if you act before the crowd does.
And with June 1 just around the corner, time is no longer on your side.
This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. If you would like to optout from receiving offers from The Oxford Club please click here.
This is Kevin Vander with “10XProTrader” delivering you your new premarket breakout alert for today’s trading session.
Wall Street is Showing Major Interest in TDIC, QUCY, FCHL this Morning!
Dreamland Limited (NASDAQ: TDIC) is surging in pre-market this morning, make sure you have it pulled up on your trading screen.
Quantum Cyber N.V. (NASDAQ: QUCY) is surging in pre-market this morning, make sure you have it pulled up on your trading screen.
Fitness Champs Holdings Limited (NASDAQ: FCHL) is surging in pre-market this morning, make sure you have it pulled up on your trading screen.
Kevin Vander
Chief Strategist, 10XProTrader
@ 2026 10XProTrader.. All Rights Reserved. You are receiving this e-mail as part of your subscription to 10XProTrader. Nothing in this email should be considered personalized fina·ncial advice. 10XProTrader is neither a registered inve·stment adviser nor a broker/dealer. Readers are advised that this electronic publication is issued solely for information purposes only and should not be construed as an offer to s·ell or the solicitation of an offer to b·uy any sec·urity. 10XProTrader is a fina·ncial publisher that does not offer any personal fina·ncial advice or advocate the p·urchase or s·ale of any sec·urity or inve·stment for any specific individual. This communication is not a sponsored adv·ertisement.
@ 2026 10XProTrader, 340 Royal Poinciana Way Suite 317, Palm Beach, FL 33480, United States of America
Featured: The Fed Chair Vote Is Here. Don’t Look Away. Sponsored
This Pre-IPO Window Is Closing. Why 7,000+ People Got In Early.
Round closes May 14th, 2026
Not every company makes it from seed to public markets. The ones that do tend to share a pattern: real users, real revenue, strategic partners locked in, and a clear path to liquidity.
Immersed is partnered with the tech giants and checks every box.
THE IMMERSED SCORECARD✓4,000% valuation growth since founding ✓$28M+ raised from over 7,000 retail investors ✓NASDAQ ticker reserved: $IMRS. Path to public markets is clear. ✓Strategic partnerships with Meta, Microsoft, Qualcomm, and Samsung✓No. 1 productivity app in the Meta Quest Store, 1.5M+ active users ✓Covered in Time, Wired, Forbes, CNET, and TechCrunch
This is a paid advertisement for Immersed Regulation A+ offering. Please read the offering circular at invest.immersed.com
The valuation is set by the Company and there is currently no public market for the Company’s Common Stock. NASDAQ ticker “IMRS” has been reserved by Immersed and any potential listing is subject to future regulatory approval and market conditions. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Forward-looking statements appear here based on current information. They involve known and unknown risks, uncertainties, and other factors that may cause outcomes to differ.
FEATURED
The Fed Chair Vote Is Here. Don’t Look Away.
The Senate voted 51-45 yesterday to confirm Kevin Warsh to the Federal Reserve’s Board of Governors. One Democrat crossed the aisle – Sen. John Fetterman of Pennsylvania. Every Republican who showed up voted yes. The chair vote, which is a separate confirmation, is expected as soon as tonight or tomorrow, ahead of Jerome Powell’s term expiring on Friday, May 15.
This is not a small thing.
The Federal Reserve hasn’t had a leadership transition this politically charged in decades. And the person stepping into that chair has already told anyone who would listen that he wants what he calls “regime change” at the central bank. Not a tweak. Not a pivot. A structural overhaul of how the institution operates, communicates, and coordinates with the Treasury.
So let’s talk about what’s actually changing, what probably isn’t, and where the market is getting ahead of itself.
Who Is Kevin Warsh
Warsh, 55, is not a newcomer. He served on the Fed’s Board of Governors from 2006 to 2011, spanning the global financial crisis, and built a reputation during that stretch as an inflation hawk who was skeptical of the Fed’s expanding mandate and balance sheet. He graduated from Stanford and Harvard Law, spent years at Morgan Stanley in M&A, then moved into the Bush White House as a special assistant for economic policy. After leaving the Fed in 2011, he spent time as a Hoover Institution fellow and as an adviser to Stanley Druckenmiller.
Trump nominated him in late January of this year. The path to confirmation got complicated fast.
Sen. Thom Tillis (R-NC), a Banking Committee member, blocked the nomination until the Justice Department concluded its criminal investigation into Powell over testimony he gave to the Senate about the Fed’s $2.5 billion headquarters renovation. The DOJ dropped that investigation late last month. Tillis confirmed he was ready to vote yes. The Banking Committee advanced Warsh on a party-line vote, and the full Senate followed yesterday.
Slight tangent, but it matters – Powell is actually staying. He told reporters he will remain on the Board as a rank-and-file governor, which would make him the first outgoing Fed chair in more than 75 years to do so. His governor term runs through January 2028. His stated reason: protecting the institution from what he described as “legal attacks” threatening the Fed’s ability to conduct monetary policy without political interference. That’s a real dynamic Warsh will have to manage from day one.
Sponsored
Wall Street Issues Dire Warning to Clients
Wall Street has issued a chilling warning for anyone with money in the U.S. stock market right now. Top analysts at these banks say a big event is coming that could both wipe out the market and keep it down for 10 years or longer. What can you do? A new tech breakthrough from a firm in Baltimore, Maryland may hold the answer.
Here’s where it gets interesting. Warsh’s public positioning has shifted meaningfully from his earlier hawkish days. During his confirmation hearing on April 21, he expressed openness to lower rates – not because the economy demands it, but because he believes a smaller Fed balance sheet, tighter coordination with Treasury on non-monetary policy, and productivity gains from AI could create room to ease. In a November 2025 Wall Street Journal op-ed, he wrote that AI would be “a significant disinflationary force.” Senators pressed him on whether that view held given the current energy shock. He gave no clean answer.
Deutsche Bank analysts put it more precisely: Warsh should not be read as structurally dovish. His views “have tended to skew hawkish relative to others.” The argument that a smaller balance sheet creates room for rate cuts is a long-horizon thesis. It doesn’t move rates in June.
What he confirmed during the hearing:
He wants to shrink the Fed’s balance sheet. He believes doing so will help temper inflation and over time open the door to lower borrowing costs.
He floated the idea of reducing the number of annual FOMC meetings from eight. He said four isn’t enough, and more than four is appropriate – but he declined to commit to eight. That’s a bigger operational shift than it sounds.
He told senators Trump never asked him to predetermine any interest rate decision. He pledged independence. Sen. Warren called him a “sock puppet.” He denied it.
He said he will divest the majority of his roughly $100 million in assets before confirmation, with the rest within 90 days.
Trump, for his part, told CNBC he would be “disappointed” if Warsh doesn’t cut rates. That comment is already priced into the political backdrop. What it actually means for monetary policy is a different question entirely.
Where Rates Stand Right Now
The Fed cut 75 basis points total in the final three meetings of 2025, landing the federal funds rate at the current target range of 3.50%–3.75%. Since then, the FOMC has held rates steady for three consecutive meetings in January, March, and April 2026 – all in line with expectations. The April vote was notably fractured: an 8-4 dissent, the first time since October 1992 that four officials disagreed with a single FOMC decision.
The friction point is inflation. A surge in energy prices tied to the U.S.-Israel war on Iran has pushed inflation higher and complicated the Fed’s path. Financial markets are currently pricing roughly a one-in-three chance of a rate hike by December. That’s not a base case – it’s a tail risk that’s grown large enough to be worth watching. The FOMC minutes from March showed that a majority of participants judged that upside risks to inflation had increased, and that a prolonged Middle East conflict would likely lead to more persistent energy price increases passing through to core inflation.
The Fed’s next scheduled meeting is June 16–17. That will almost certainly be Warsh’s first as chair.
The Independence Question Is the Real Story
Here’s what most of the coverage is underweighting. The structural tension isn’t really about whether rates go up or down in June. It’s about whether the Federal Reserve’s decision-making process remains insulated from the executive branch over a multi-year horizon.
Warsh has proposed tighter coordination between the Fed and Treasury on non-monetary policies. Trump has attempted to fire at least one Biden-era Fed governor – a case currently before the Supreme Court. The DOJ investigated the sitting Fed chair. Powell is staying on the board specifically to push back on what he sees as institutional erosion. And Warsh, whatever his intentions, was nominated by an administration that has been explicit about wanting the Fed aligned with its economic agenda.
Worth noting: the Fed chair has only one of twelve votes on the FOMC. Warsh can advocate – but he cannot unilaterally cut rates. Any meaningful policy shift requires building a coalition among governors and regional Fed presidents. Several of those seats are held by Biden nominees. The board dynamics are not going to be frictionless.
That’s the part people skip. Warsh is a persuader-in-chief, not a sole decision-maker.
Sponsored
Wall Street is calling it the “Warsh Shock.” Here’s how to profit from it…
Larry Benedict isn’t scrambling. He’s seen this before.
He says the Warsh Shock is setting up the most predictable wealth-building window he’s seen in 20 years… and there’s one ticker right at the center of it.
The chair confirmation vote lands as early as tonight – ahead of Powell’s May 15 term expiration. After that, the immediate calendar looks like this:
June 16–17: First FOMC meeting under Warsh. No rate move is expected, but the statement language and press conference will get intense scrutiny. Any shift in tone from Powell-era communication will move markets.
Balance sheet trajectory: Warsh has been clear that he wants the balance sheet smaller. How aggressively and on what timeline is the first real policy signal investors should track.
Meeting frequency: If Warsh moves toward fewer than eight annual FOMC meetings, that changes forward guidance mechanics and how markets price rate expectations throughout the year.
FOMC composition: The Supreme Court case on firing Fed governors is unresolved. If the court rules in the administration’s favor, the board’s composition could shift in ways that matter for the vote count on any contentious decision.
Energy and inflation: None of the above matters much if CPI keeps climbing. The Iran-driven energy shock is the wildcard that could force Warsh’s hand before any structural reforms gain traction.
What’s interesting is that the market’s immediate reaction to Warsh’s April 21 hearing was muted and slightly negative. The S&P 500 and Nasdaq each fell roughly 0.4% that day, pausing a rally that had pushed both indexes to record highs. Nothing about that reaction screamed “investors love this.” It said: investors are uncertain, and uncertainty at the Fed is a premium risk right now given the inflation backdrop.
Bottom line: Warsh gets the title. What he does with it is the question that won’t be answered in a single press conference or a single FOMC statement. The June 16 meeting is the first real data point. Between now and then, watch the communication style, watch the balance sheet language, and watch what happens with the Supreme Court case. The structural changes Warsh is talking about – a Treasury-Fed accord, fewer meetings, a smaller balance sheet – are multi-year projects, not quarter-to-quarter trades. The market will price in expectations long before any of it materializes.
The chair is new. The inflation problem is not.
– The Cheap Investor
This content is for informational purposes only and should not be considered financial advice. Investing involves risk.
The Cheap Investor is a publication of Investing Media Solutions, LLC.
Artificial intelligence was supposed to become the ultimate asset-light software revolution.
Instead, it increasingly appears to be becoming an infrastructure arms race.
That distinction matters enormously.
The market still largely assumes hyperscalers eventually transition from: aggressive AI investment to massive margin harvesting.
But the economics emerging underneath machine-scale compute may suggest something very different: continuous infrastructure expansion, persistent thermal scaling, and structurally elevated capex requirements.
That’s where Vertiv becomes important.
The company sits directly inside one of the most unavoidable bottlenecks in the AI economy: cooling the machines.
As GPU rack-density rises and inference workloads expand, thermal-management systems are becoming increasingly strategic across hyperscale infrastructure environments. AI clusters built around next-generation accelerators consume dramatically more power — and generate dramatically more heat — than traditional cloud architecture.
The machines still need to stay cool.
That may sound operationally simple.
Economically, it may become one of the most important infrastructure constraints in the entire AI system.
Most investors still appear to view AI infrastructure demand primarily as a powerful semiconductor cycle.
Our ALDI framework suggests something more structural may be forming: a long-duration physical rebuild of the AI economy itself.
ALDI SCORES — Vertiv (VRT)
• ALDI Pressure: 94 The scale of AI infrastructure expansion increasingly suggests corporations expect machine intelligence to become deeply embedded throughout enterprise systems, creating persistent demand for compute-intensive infrastructure
• ALDI Score: +86 Vertiv appears structurally positioned inside one of the most unavoidable bottlenecks in the AI economy: thermal management and cooling systems required to support rising machine-density and hyperscale AI clusters
• Mispricing Score: +39 (Buy) The market recognizes Vertiv as an AI infrastructure beneficiary, but may still underestimate how structurally persistent cooling and thermal-management demand could become underneath continuous AI infrastructure escalation
ALDI Pressure (0–100) measures how intense AI-driven labor disruption is within a company; ALDI Score (–100 to +100) measures whether a company benefits or is harmed by that disruption; Mispricing Score (–100 to +100) measures the gap between underlying reality and market expectations. Scores above +20 indicate Buy opportunities, below –20 indicate Sell signals.
The most durable AI investments may not ultimately be the companies attempting to dominate artificial intelligence itself.
They may be the firms quietly monetizing the physical infrastructure the hyperscalers cannot avoid building.
AI Investor Pro analyzes how AI-driven labor disruption is reshaping margins, infrastructure demand, organizational scaling and long-term market leadership. Our focus is not generic AI commentary — it is identifying where the market may still be underpricing the second-order economic effects of artificial intelligence.Share on:Facebook|Threads|X|LinkedIn
Just Announced | (Nasdaq: FMST)Expands Its Uranium Zone And Starts A New Drill Program This Morning
Dear Reader,
We have been watching this one closely — and what just crossed the wire this morning gives us even more reason to keep our eyes on it.
Foremost Clean Energy Ltd. (Nasdaq: FMST)just announced the successful completion of its 2026 drill program at the Hatchet Lake South Uranium Project in the eastern Athabasca Basin region of northern Saskatchewan — and the results are continuing to build on what has been an encouraging run of exploration progress.
Here is what stood out: the final drill fence of the program returned a new mineralized intercept in hole TF-26-36, intersecting 0.18% eU₃O₈ over 2.9 metres and extending the northern extent of uranium mineralization by approximately 100 metres. Across the full 2026 program, uranium mineralization was intersected in six drillholes across four of five drill fences completed — including the high-grade interval of 1.0% eU₃O₈ over 1.4 metresreturned earlier in the program.
And the story does not stop there.
Approximately 600 metres of conductive strike length remains open to the south and largely untested — meaning the Tuning Fork Uranium Zone still has significant room to grow.
CEO Jason Barnard called the results a“strong foundation for follow-up drilling” and confirmed the company has already commenced drilling at the Richardson SE target on Hatchet Lake North, where more than 5 kilometres of untested electromagnetic conductor strike length are waiting to be evaluated.
This is an active, moving exploration story in one of the world’s most recognized uranium jurisdictions — and (FMST) is on our watchlist right now.
If you missed our earlier coverage, keep reading to quickly get up to speed on why we’re so excited to be highlighting (FMST) today.
=====
At Street Ideas, we spend a lot of time tracking early shifts before the broader market fully catches on—and this morning, Wednesday, May 13, 2026, Foremost Clean Energy Ltd. (NASDAQ: FMST) has forced its way back onto our radar in a major way.
The uranium sector has been quietly tightening for months, but the story around (FMST) appears to be accelerating fast following two back-to-back press releases over the last three weeks that significantly expanded the scope of its exploration story.
The latest drill updates now point to a rapidly growing high-grade uranium zone confirmed across multiple drill fences inside one of the most important uranium jurisdictions on the planet.
With fewer than 12M shareslistedas available to the public, a $9M exploration budget, and fresh geophysical data now pointing toward a second active drilling front, the setup heading into the summer months deserves a close look.
A Company Built for This Moment
Foremost Clean Energy (NASDAQ: FMST) is a North American uranium and lithium exploration companystrategically positioned to benefit from the accelerating demand for reliable, carbon-free energy.
The company holds an option fromDenison Mines Corp to earn up to 70% interest in 10 uranium properties—with up to 51% at Hatchet Lake—spanning over 330,000 acres in the Athabasca Basin of northern Saskatchewan, one of the world’s most uranium-rich jurisdictions.
This region is historically known to host some of the richest uranium deposits on the planet, with average grades running 10X to 100X higher than the global average while supplying approximately 15% of the world’s primary uranium output.
The company’s data-driven exploration strategy is backed by decades of historical drilling and geophysical data from Denison, providing a validated roadmap for targeting high-potential mineralized trends.
Beyond uranium, (FMST) also controls a large land position in Manitoba’s Snow Lake district—a region the company refers to as“Lithium Lane”—offering dual-commodity exposure to both the nuclear renaissance and the electrification movement.
AI Meets the Uranium Bottleneck
The story behind (FMST) is inseparable from the energy crisis quietly building behind the AI boom.
Data centers already consume roughly 1.5% of global electricity—and that consumption is accelerating at approximately 30% per year. The grid simply cannot keep up.
Nuclear power has emerged as the only scalable, always-on, carbon-free solution capable of meeting data center baseload demand.
With Russia maintaining a dominant position in global processed uranium supply, the push for secure, Tier-1 North American sources has become a matter of national security, not just market economics.
That is the structural wind at (FMST)’sback.
What Just Put (FMST) Back on Our Radar
Two significant developments have unfolded in the past three weeks—and taken together, they materially strengthen (FMST)’s exploration thesis.
These results build directly on the 2025 discovery in hole TF-25-16. Step-out drilling across three separate drill fences has now expanded the mineralized footprint of what is officially designated the “Tuning Fork Uranium Zone” to over 150 metres of strike length—a compelling demonstration of system continuity in an area that remains open in multiple directions.
To date, a total of 10 diamond drill holes spanning 2,113 metres have been completed at the zone.
Five of those holes returned uranium mineralization meeting or exceeding the reporting threshold of 0.05% eU₃O₈.
What stands out just as much: every single completed hole encountered anomalous radioactivity above 2x background andhydrothermal alteration at the Athabasca unconformity—a geological fingerprint consistent with the district’s most significant deposits.
As President and CEO of Foremost, Jason Barnard stated, the results “demonstrate the growing scale of the system” and the company is “well positioned to keep expanding this area through continued drilling.”
CLK Uranium Property: Geophysics Points the Way
On May 5, 2026, (FMST) released a second update that opens an entirely new front in the exploration story.
The first was a helicopter-borne MobileMT electromagnetic and magnetic survey covering 808 line-kilometresacross the 136 km² property block, mapping conductive and resistive anomalies from surface to depths exceeding 900 metres.
Both datasets are now being integrated to define high-priority drill targets near historical hole CLG-D1, which intersected approximately 1.01% U₃O₈ at 862 metres depth from visible pitchblende stringers just below the unconformity.
The CLK Property is already fully permitted for a multi-phase program including up to 30 diamond drill holes—meaning the company can move quickly once targets are defined.
Financial and Structural Profile
Heading into its most active exploration season, (FMST)’s capital position is solid. The company closed a Canaccord Genuity-led bought deal private placement on March 31, 2026, raising approximately C$5.75M in aggregate gross proceeds to fund qualifying Canadian exploration through December 2027. The 1,690,200 flow-through units were priced at C$3.40 each, with each unit including one common share and one-half warrant exercisable at C$4.40 until March 2028.
The company’s total2026 exploration budgetstands at approximately $9M, with roughly 11,500 metres of total drilling planned across all projects—making this its most operationally active year to date. Insider alignment is tight: management and directors hold approximately 4.65% of shares, and when combined with Denison’s 17.06%strategic stake, roughly 21.71% of the company is held by aligned insiders and a major institutional partner.
With fewer than 12M shares available to the public, (FMST)’s small float could see the potential for big moves if demand begins to shift.
7 Reasons (FMST) is Topping Our Watchlist This Morning
Wednesday, May 13, 2026…
1. Nuclear Is Booming: The Bank of America recently identified nuclear energy as a potential $10T market in the coming years, and (FMST) is positioned in one of the world’s most uranium-rich regions to potentially benefit from that wave.
2. Big Tech Needs Power: Meta, Google, Amazon, and Microsoft are collectively pouring an estimated $650B into AI infrastructure in 2026 alone, and (FMST)is exploring for the uranium needed to fuel the nuclear power those data centers increasingly depend on.
3. America’s Supply Gap: The U.S. produced less than 1% of its own uranium needs in 2024 while reactor buyers acquired over 50M lbs—a massive domestic shortfall that makes North American explorers like (FMST)increasingly relevant.
4. Drill Program Delivering:(FMST)’s2026 drill program at Hatchet Lake has now confirmed uranium mineralization across 150 metres of strike length, with the zone still open in multiple directions and more results pending.
5. Small Float: With fewer than 12M shares available to the public, (FMST)has one of the tighter floats in the sector, which historically means a smaller number of shares need to change hands to move the needle.
6. Fully Funded: With approximately C$5.75M raised through a bought deal in March 2026, (FMST) has the capital in place to execute its largest exploration program to date without needing to immediately raise additional funds.
7. Nvidia Just Went Nuclear:(FMST) is advancing uranium exploration at a moment when even Nvidia has begun partnering with nuclear start-up Oklo—a signal that the world’s most influential tech companies are now directly linking their future to nuclear energy.
The case for Foremost Clean Energy (NASDAQ: FMST) comes together quickly when you step back and look at the full picture.
Bank of America sees nuclear as a potential $10T market. The biggest names in tech are spending $650B on AI infrastructure that ultimately needs reliable, carbon-free power to run. The U.S. is producing less than 1% of its own uranium while buying over 50M lbs from foreign sources every year.
And now Nvidia—one of the most closely watched companies in the world—is linking its future directly to nuclear energy.
Against that backdrop, (FMST) is actively drilling in one of the world’s most uranium-rich jurisdictions, has just confirmed mineralization across 150 metres of strike length at Hatchet Lake with results still pending, and closed a fresh C$5.75M financing to fund the work.
With fewer than 12M shares available to the public, the company is built lean at a moment when the macro tailwinds behind uranium have rarely been this well-defined.
The fundamentals, the timing, and the operational momentum are all pointing in the same direction.
We have all eyes on (FMST) this morning—Wednesday, May 13, 2026.
Take a look at (FMST) this now, before the bell rings.
Also, keep a look out for my next update—it could be hitting very shortly.
Sincerely,
Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter
Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Foremost Clean Energy Ltd. (FMST:US) (FAT:CA) previously changed their company name from Foremost Lithium Resource & Technology Ltd. (FMST:US) (FAT:CA)
Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 05/13/2026 and ending on 05/13/2026 to publicly disseminate information about (FMST:US) (FAT:CA) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, 147 Media LLC has been paid forty eight thousand USD (“Funds”). These Funds were part of the twenty two thousand five hundred USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither 147 Media LLC, TD Media LLC and their member own shares of (FMST:US) (FAT:CA).
Still On It | (Nasdaq: MBRX) Pops Approx. 12% And Krypton Street is Still Covering It
Dear Reader,
The update on Moleculin Biotech, Inc. (Nasdaq: MBRX) is here — and the early move this morning says a lot.
(MBRX) alreadyreached $2.61 today, marking an approximate 12% move off yesterday’s $2.32range — and Krypton Street has had its eyes on it all morning.
The catalyst is this morning’s major clinicalannouncement, confirming the first MIRACLE trial unblinding remains on track before June 30, 2026 — with a composite complete remission rate exceeding 40% and an approximate 30% complete remission ratecontinuing to outperform the historical cytarabine benchmark of roughly 17-18%.
(MBRX) is not flying under the radar anymore — and Krypton Street wants to make sure you are not either.
Take a few minutes to scroll down and get the full picture on why (MBRX)earned the top spot on our watchlist today.
=====
Krypton Street is tracking a little-known Phase 3 biotech that could be approaching one of its most important clinical milestones yet.
Preliminary blinded data from the first 30 subjects showed a 40% composite complete remission rate, approximately67% above the historical response rate for standard cytarabine alone, while management has publicly stated interim Phase 3 data is expected later this quarter.
That is part of the reason why Moleculin Biotech, Inc. (Nasdaq: MBRX) just hit our radar and is climbing toward the top of this morning’s watchlist—Wednesday, May 13, 2026.
But keep in mind, (MBRX) has less than 6M shareslisted as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift.
Recently, (MBRX) made an approximate 50% move in just over a month when it went from around $1.79 on March 9 to $2.72 on April 14, according to Barchart.
That kind of setup is exactly what can put a little-known biotech under a much brighter spotlight in a very short window.
And with a pivotal clinical update now expected before quarter-end, (MBRX)could start to draw attention from more than just our desk.
Analyst Targets Point To 300%–800% Upside Potential…
Sara Nik ofH.C. Wainwright has a $22 target on (MBRX), which suggests over 800% upside potential from its recent $2.40 range. Jason McCarthy ofMaxim Group reiterated a $10 target less than two weeks ago, which suggests over 300% upside potential from current levels.
Two covering analysts, two significant targets, one imminent data readout.
(MBRX) ended 2025 with $8.9M in cashand raised an additional $8.3M in gross proceeds through financing activities in Q1 2026. Management hasconfirmed it expects combined resources to fund planned operations into Q3 2026 — through and beyond the anticipated MIRACLE interim readout.
But the analyst targets and near-term clinical timing are only part of the story.
To understand why (MBRX) is drawing this level of attention, you have to look at the science behind the pipeline itself.
A Pipeline Built for Cancers That Fight Back
Moleculin Biotech, Inc. (Nasdaq: MBRX) is a Houston-based, late-stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses.
Its lead program,Annamycin (naxtarubicin), is a next-generation anthracycline engineered with two critical advantages over older agents like doxorubicin: it is designed to avoid multidrug resistance mechanisms, and it lacks the cardiotoxicity that has long constrained the use of conventional anthracyclines.
Across more than 100 patients treated in Moleculin’s clinical programs to date, no associated cardiotoxicity has been reported — a documented safety differentiator that could matter considerably in regulatory and commercial discussions.
Annamycin is being evaluated in theMIRACLE trial — a pivotal, global Phase 2B/3 study combining Annamycin with cytarabine (AnnAraC) for adult R/R AML patients following induction therapy.
The trial is enrolling across eight countries in the United States and Europe.
The company has also completed a successful Phase 1B/2 study (MB-106) that, with FDA input, it believes has substantially de-risked the regulatory pathway toward a potential new drug approval.
Beyond AML, the pipeline includes Annamycin forsoft tissue sarcoma lung metastases; WP1066, an immune and transcription modulator targeting brain tumors and other cancers; and WP1122, an antimetabolite being explored for viral indications.
(MBRX) is a multi-indication platform with AML leading the charge.
The Market Moleculin Is Targeting
The globalAML treatment market was valued at approximately $3.87B in 2025and is projected to expand at a CAGR of roughly 10.6%, reaching an estimated $9.62B by 2034.
The American Cancer Society estimates 22,010 new AML diagnoses in the United States in 2025 alone, with approximately 11,090 expected deaths. For the relapsed or refractory subset — Moleculin’s specific target population — the unmet need is especially severe: standard high-dose cytarabine (HiDAC) produces complete remission rates of only around 17-18%, leaving the vast majority of patients without durable responses.
That is the gap AnnAraC is designed to fill.
The preliminary blinded 40% composite complete remission rate observed across the first 30 MIRACLE subjects — of whom approximately 35% had already failed prior venetoclax-based therapy, among the most resistant patients — supports the view that AnnAraC may be performing meaningfully above the standard of care. Full unblinded confirmation is expected this quarter.
A Cascade of Recent Potential Catalysts
On May 8, 2026, Moleculinannounced a new Hong Kong patent (No. 40073244) covering its proprietary method of reconstituting liposomal Annamycin, extending IP protection through June 25, 2040.
The timing is deliberate.
CEO Walter Klempstated directly: “This level of patent protection is made all the more important given the expected timing of our first Phase 3 clinical data release later this quarter.”
(MBRX)’s global IP now spans four continents.
On April 23, new preclinical data presented at theAACR Annual Meeting 2026 showed Annamycin extending survival by more than 60% in metastatic pancreatic cancer preclinical models, with significantly greater tumor tissue accumulation than doxorubicin (p<0.0001), and evidence of CD8+ and CD4+ T cell infiltration — suggesting potential to activate immune responses in notoriously cold tumors.
An abstract highlighting Annamycin data has also been accepted for poster presentation at the 2026 ASCO Annual Meeting, one of oncology’s most influential annual gatherings, placing Annamycin in front of a global clinical audience at exactly the right moment.
May 13, 2026: 7 Reasons Why (MBRX) Has Earned The Top Spot On Our Watchlist This Morning…
1. Recent Momentum: After moving from around $1.79 on March 9 to $2.72 on April 14, (MBRX) already showed an approximate 50% move in just over a month.
2. Small Float: With fewer than 6M shares listed as available to the public, (MBRX)’s small float could witness the potential for big moves if demand begins to shift.
3. Analyst Targets: With targets of $10and $22, (MBRX) has analyst coverage which suggests over 300% to 800% upside potential from its recent $2.40 range.
4. Clinical Timing: With MIRACLE interim data expected later this quarter, (MBRX)has a near-term readout that could draw added attention.
5. Early Signal: Based on preliminary blinded results from the first 30 subjects, (MBRX) showed a 40% composite complete remission rate.
6. Patent Coverage: Following a new Hong Kong patent extending protection through June 25, 2040, (MBRX) now has global IP spanning four continents.
7. Capital Position: After ending 2025 with $8.9M in cash and raising another $8.3M in Q1 2026, (MBRX) says resources should fund planned operations into Q3 2026.
Get (MBRX) On Your Radar While It’s Still Early…
Taken together, the setup surrounding (MBRX) is difficult to ignore right now. Between the small public float, the recent approximate 50% move in just over a month, analyst targets ranging from $10 to $22, and a pivotal MIRACLE interim data readout expected later this quarter, multiple factors are beginning to converge at the same time.
Add in the preliminary 40% compositecomplete remission rate, capital resources projected into Q3 2026, and expanding patent protection across four continents, and it becomes clear why (MBRX) just hit our radar.
(MBRX) has our full attention this morning.
Take a look at (MBRX) while it’s still early.
My next update could be on the way shortly, so keep watch.
Sincerely,
Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter
KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 05/13/2026 and ending on 05/13/2026 to publicly disseminate information about (MBRX:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid thirty seven thousand five hundred USD (“Funds”). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Media 1717 LLC, TD Media LLC and their member own shares of (MBRX:US).
Still Watching (Nasdaq: MBRX) | Why The Approx. 12% Move Is Just Part Of The Story
Dear Reader,
Market Crux has one name at the top of its radar this morning — and it has already moved approximately 12%.
Moleculin Biotech, Inc. (Nasdaq: MBRX)hit $2.61 today, up from yesterday’s $2.32range — a move that started the moment this morning’s clinicalupdatecrossed the wire.
The release confirmed the first MIRACLE trial unblinding is on track before June 30, 2026, with preliminary blinded data continuing to significantly outperform historical benchmarks — a composite complete remission rate exceeding 40%and an approximate 30% complete remission rate against a historical cytarabine rate of roughly 17-18%.
The data is holding, the date is set, and (MBRX) is already responding.
Scroll down for everything Market Cruxhas been tracking on (MBRX) since the news dropped this morning.
=====
Market Crux has its eye on a little-known Phase 3 biotech that appears to be closing in on what could be the most consequential clinical milestone in its history. Preliminary blinded results from the first 30 trial subjectscame in at a 40% composite complete remission rate — roughly 67% above the historical response rate for standard cytarabine alone — and management has since confirmed that interimPhase 3 datais expected before the end of this quarter.
Those are two of the reasons Moleculin Biotech, Inc. (Nasdaq: MBRX) just hit our radar this Wednesday morning, May 13, 2026.
But keep in mind, (MBRX) has less than 6M shareslisted as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift.
Recently, (MBRX) made an approximate 50% move in just over a month when it went from around $1.79 on March 9 to $2.72 on April 14, according to Barchart.
That kind of setup is exactly what can put a little-known biotech under a much brighter spotlight in a very short window.
And with a pivotal clinical update now expected before quarter-end, (MBRX)could start to draw attention from more than just our desk.
Analyst Targets Point To 300%–800% Upside Potential…
Sara Nik ofH.C. Wainwright has a $22 target on (MBRX), which suggests over 800% upside potential from its recent $2.40 range. Jason McCarthy ofMaxim Group reiterated a $10 target less than two weeks ago, which suggests over 300% upside potential from current levels.
Two covering analysts, two significant targets, one imminent data readout.
(MBRX) ended 2025 with $8.9M in cashand raised an additional $8.3M in gross proceeds through financing activities in Q1 2026. Management hasconfirmed it expects combined resources to fund planned operations into Q3 2026 — through and beyond the anticipated MIRACLE interim readout.
But the analyst targets and near-term clinical timing are only part of the story.
To understand why (MBRX) is drawing this level of attention, you have to look at the science behind the pipeline itself.
What Is Actually Inside The (MBRX) Pipeline
Moleculin Biotech, Inc. (Nasdaq: MBRX) is a Houston-based, late-stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses.
Its lead program,Annamycin (naxtarubicin), is a next-generation anthracycline engineered with two critical advantages over older agents like doxorubicin: it is designed to avoid multidrug resistance mechanisms, and it lacks the cardiotoxicity that has long constrained the use of conventional anthracyclines.
Across more than 100 patients treated in Moleculin’s clinical programs to date, no associated cardiotoxicity has been reported — a documented safety differentiator that could matter considerably in regulatory and commercial discussions.
Annamycin is being evaluated in theMIRACLE trial — a pivotal, global Phase 2B/3 study combining Annamycin with cytarabine (AnnAraC) for adult R/R AML patients following induction therapy.
The trial is enrolling across eight countries in the United States and Europe.
The company has also completed a successful Phase 1B/2 study (MB-106) that, with FDA input, it believes has substantially de-risked the regulatory pathway toward a potential new drug approval.
Beyond AML, the pipeline includes Annamycin forsoft tissue sarcoma lung metastases; WP1066, an immune and transcription modulator targeting brain tumors and other cancers; and WP1122, an antimetabolite being explored for viral indications.
(MBRX) is a multi-indication platform with AML leading the charge.
A $9.62B Market By 2034 — And A Treatment Gap
That Still Exists Today
The globalAML treatment market was valued at approximately $3.87B in 2025and is projected to expand at a CAGR of roughly 10.6%, reaching an estimated $9.62B by 2034.
The American Cancer Society estimates 22,010 new AML diagnoses in the United States in 2025 alone, with approximately 11,090 expected deaths. For the relapsed or refractory subset — Moleculin’s specific target population — the unmet need is especially severe: standard high-dose cytarabine (HiDAC) produces complete remission rates of only around 17-18%, leaving the vast majority of patients without durable responses.
That is the gap AnnAraC is designed to fill.
The preliminary blinded 40% composite complete remission rate observed across the first 30 MIRACLE subjects — of whom approximately 35% had already failed prior venetoclax-based therapy, among the most resistant patients — supports the view that AnnAraC may be performing meaningfully above the standard of care. Full unblinded confirmation is expected this quarter.
Recent Milestones
On May 8, 2026, Moleculinannounced a new Hong Kong patent (No. 40073244) covering its proprietary method of reconstituting liposomal Annamycin, extending IP protection through June 25, 2040.
The timing is deliberate.
CEO Walter Klempstated directly: “This level of patent protection is made all the more important given the expected timing of our first Phase 3 clinical data release later this quarter.”
(MBRX)’s global IP now spans four continents.
On April 23, new preclinical data presented at theAACR Annual Meeting 2026 showed Annamycin extending survival by more than 60% in metastatic pancreatic cancer preclinical models, with significantly greater tumor tissue accumulation than doxorubicin (p<0.0001), and evidence of CD8+ and CD4+ T cell infiltration — suggesting potential to activate immune responses in notoriously cold tumors.
An abstract highlighting Annamycin data has also been accepted for poster presentation at the 2026 ASCO Annual Meeting, one of oncology’s most influential annual gatherings, placing Annamycin in front of a global clinical audience at exactly the right moment.
Here Are 7 Reasons Why (MBRX) Is Leading Our Watchlist On This Wednesday Morning—May 13, 2026
1. The Float Is Smaller Than Most Realize: With fewer than 6M shares listed as available to the public, (MBRX)’s small float could witness the potential for big moves if demand begins to shift.
2. Approximately 50% In Just Over A Month : After moving from around $1.79 on March 9 to $2.72 on April 14, (MBRX)already showed an approximate 50% move in just over a month.
3. Analyst Targets: With targets of $10and $22, (MBRX) has analyst coverage which suggests over 300% to 800% upside potential from its recent $2.40 range.
4. Clinical Timing: With MIRACLE interim data expected later this quarter, (MBRX)has a near-term readout that could draw added attention.
5. Early Signal: Based on preliminary blinded results from the first 30 subjects, (MBRX) showed a 40% composite complete remission rate.
6. Patent Coverage: Following a new Hong Kong patent extending protection through June 25, 2040, (MBRX) now has global IP spanning four continents.
7. Balance Sheet Ready: After ending 2025 with $8.9M in cash and raising another $8.3M in Q1 2026, (MBRX) says resources should fund planned operations into Q3 2026.
Now Is The Time To Get (MBRX) On Your Screen…
Taken together, the setup surrounding (MBRX) is difficult to ignore right now. Between the small public float, the recent approximate 50% move in just over a month, analyst targets ranging from $10 to $22, and a pivotal MIRACLE interim data readout expected later this quarter, multiple factors are beginning to converge at the same time.
Add in the preliminary 40% compositecomplete remission rate, capital resources projected into Q3 2026, and expanding patent protection across four continents, and it becomes clear why (MBRX) just hit our radar.
All eyes at MarketCrux are on (MBRX) right now.
Pull up (MBRX) while it’s still early.
Keep an eye on your inbox — my next update could arrive sooner than you think.
Sincerely,
Gary Silver
Managing Editor,
MarketCrux
MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 05/13/2026 and ending on 05/13/2026 to publicly disseminate information about (MBRX:US) via digital communications. Under this agreement, TD Media LLC has paid Headline Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid thirty two thousand five hundred USD (“Funds”). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Headline Media LLC, TD Media LLC and their member own shares of (MBRX:US).
When the leaders of the world’s two largest economies sit down for talks, markets pay attention. When those talks include the CEOs of two of America’s most valuable tech companies,…
The market just experienced a reality check that’s forcing investors to rethink everything they thought they knew about the next two years. Following a surprisingly hot inflation…
“I recently visited Mar-a-Lago… And now I’m prepared to put my reputation on the line. One investment I just uncovered could be my biggest winner of all… It involves President Trump, Elon Musk, trillions of dollars, China… And a MAJOR upgrade to the artificial intelligence revolution. If you buy just one stock in 2026, I urge you to make it this one.” – Louis Navellier
The semiconductor sector got a double dose of optimism this week. First, Nvidia’s Jensen Huang accepted an invitation to join President Trump’s upcoming diplomatic visit to China. Second,…
Alibaba just posted one of the most dramatic profit drops I’ve seen from a major tech company. Core profitability collapsed 84% in the March quarter, and management’s explanation was…
Wall Street legend Marc Chaikin’s award-winning system turned bearish on software stocks two months before they crashed this year. Now, he’s warning that one AI lab’s breakthrough could CRASH the Nasdaq while igniting a $500 trillion wealth transfer. He’s found a little-known $40 “pre-IPO backdoor” into the private startup behind this economic sea change.
(Privacy Policy/Disclosures)Advertising Disclosure: This email contains paid advertisements. This email is from our associates at Investment News Daily.
Legal Entity Information: Investing Ideas Daily is owned and operated by Darwin Investor Network, a DBA of The Darwin Agency, Inc.
Disclaimer: Nothing in this email should be considered personalized financial advice. Always conduct your own due diligence when investing. We urge you to read our full disclaimer by clicking on the terms of use link below.
Unsubscribe: You are receiving this email as part of your complimentary subscription to the Investing Ideas Daily E-Letter. If you would like to unsubscribe, you can do so by clicking on the unsubscribe link below.Darwin Investor Network 2319 N Andrews Avenue, Fort Lauderdale, FL 33311 support@investingideasdaily.com | 1-800-496-9838Investing Ideas Daily | Privacy Policy | Terms of Use Unsubscribe | View Online
RJ Hamster 